{
  "page_0": "Investor\nPresentation\n888\n2024년\n2분기\n-111-1110-\nARD\nBl\ni sens\nSensing\nAhead.\nCaring\nMore",
  "page_1": "isens\nSensing\nAhead,\nCaring\nMore\n888\nOSC\n빼\nCONTENTS\nDISCLAIMER\n본\n자료에\n포함된\n예측정보는\n현재의\n사업환경을\n바탕으로\n당사의\n경영계획과\n1.\nCompany\nOverview\n전략\n등을\n고려한\n전망이며\n사업환경의\n변동\n또는\n경영계획\n및\n전략수정\n등에\n2.\nBusiness\nOverview\n따라\n달라질\n수\n있습니다.\n본\n자료는\n투자자\n여러분의\n투자판단을\n위한\n참고자료로\n작성된\n것이며,\n1)\n혈당\n부문\n당사는\n이\n자료의\n내용에\n대하여\n투자자\n여러분에게\n어떠한\n보증을\n제공하거나\n책임을\n부담하지\n않습니다.\n2)\nPOCT\n부문\n본\n자료에\n포함된\n모든\n경영실적은\nK-IFRS(한국채택국제회계기준)에\n따라\n3.\nFinancial\nOverview\n작성되었습니다.\nAppendix",
  "page_2": "i·sens\nSensing\nAhead,\nCaring\nMore\nilli-\n1.\nCompany\nOverview\n2.\nBusiness\nOverview\n1)\n혈당\n부문\n2)\nPOCT\n부문\n3.\nFinancial\nOverview\nAppendix",
  "page_3": "1.\n글로벌\n진단\n전문기업,\n아이센스\n체외진단산업\nMedical\nDevice에서\n가장\n큰\n시장,\n빠르게\n성장\n중\n(IVD:\nIn\nVitro\nDiagnostics)\nIVD\n항목별\n아이센스\n사업영역\nOthers\n자가혈당\n측정\n아이센스\n매출비중\n혈당측정\n연속혈당\n측정\n·\n자가혈당\n측정(BGM)\n85%\nMolecular\n2020년\n글로벌\n마켓\n94조\n원\n·\n연속혈당\n측정(CGM)\n2023년\n진출\nClinical\nChemistry\n현장진단(POCT)\nImmunoassays\n|\n현장진단(POCT)\n15%\n*\nSource:\n글로벌\n체외진단시장현황 및\n전망-생명공학정책연구센터(2021.11)\n2023년\n매출기준\nisens\n3",
  "page_4": "2.\n아이센스\n제품\n라인업\n혈당\n측정기\n연속혈당\n측정기\n자가혈당\n측정기\n(BGM:\nBlood\nGlucose\nMonitoring)\n(CGM:\nContinuous\nGlucose\nMonitoring)\n(11)\n103\n3\n09-24\n12:37..\n스트립\n미터\n2023년\n9월\n출시\n현장진단(POCT:\nPoint-Of-Care\nTesting)\nPOCT\n진단기기\n:\n1.8\nGripth\n병원용\n혈당기\n당화혈색소\n분석기\n혈액전해질\n분석기\n혈액가스\n분석기\n혈액응고\n분석기\n면역\n분석기\nisens\n4",
  "page_5": "3. 사업구조\n및\n주요\n고객사\n자가브랜드\nOEM/ODM\n뉴질랜드\n국가\n독점\n공급\n계약\n2012년\n~2024년\n단독\n공급\n예정\narkray\nWalmart\nSave money, Live btter.\n자가\nOEM/\n브랜드\nisens\nODM\n46%\n20%\n11%\n22%\n45%\n사업구조\n55%\nAgaMatrix\nSANOFI\n아시아(국내\n포함)\n미국\n유럽\n기타\nCVS\npharmacy\n80%\n20%\n혈당(자체브랜드)\nPOCT\n*\n2023년\n매출\n기준\n한국\n1위\nMS\n47%\nIsens\n5",
  "page_6": "i·sens\nSensing\nAhead,\nCaring\nMore\nilli-\n1.\nCompany\nOverview\n2.\nBusiness\nOverview\n1)\n혈당\n부문\n2)\nPOCT\n부문\n3.\nFinancial\nOverview\nAppendix",
  "page_7": "1.\n당뇨\n인구\n현황\n및\n전망\n당뇨\n인구는\n지속적으로\n증가\n예상\n당뇨\n인구\n전망\n5.4억 명\nCAGR\n7.8억 명\n2021년\n1.6%\n2045년\n당뇨병\n중증도\nLow\n중증도\nHigh\n90%\n100%\n당뇨\n환자\n구분 및\n비중\nType\n2\nType\n2\n(Severe)\nType\n1\n측정기기\n자가혈당\n측정기\n연속혈당\n측정기\n구분\n(BGM)\n(CGM)\n출처:\nIDF(International\nDiabetes\nFederation),\ni-SENS\nAnalysis\nisens\n7",
  "page_8": "2.\n글로벌\n시장점유율\n현황\n비교\n1)\n자가혈당\n측정기(BGM)\n2)\n연속혈당\n측정기(CGM)\nAbbott\nMedtronic\n5%\n6%\nDexcom\nRoche\n38%\nOthers\n22%\n2022년\n37%\n$7.7B\n2022년\nAbbott\n$8.3B\n56%\n(9.1조 원)\nLifeScan\n22%\nAscensia\n(단위:\n$ million)\n※\nCGM\n시장\n규모\n예상\n14%\n23,627\n출처:\nFortune\nBusiness\nInsights\nQuantitative\nData\nBlood\nGlucose\nMonitoring\nSystems-Global\nMarket\nAnalysis,\nInsights.\nand\nForecast,\n2028-2029\n9,073\n5,341\n6,497\n7,673\n2020\n2021\n2022\n2023(E)\n2029(E)\n출처:\nFortune\nBusiness\nInsights\nQuantitative\nData\nBlood Glucose\nMonitoring\nSystems-Global\nMarket Analysis,\nInsights.and\nForecast,\n2028-2029\ni sens\n8",
  "page_9": "3. 글로벌\nCGMS\n시장규모\n및\n중장기\n매출계획\nCGMS\n시장\n성장에\n따른\n아이센스의\n매출\n증가\n예상\n글로벌\nCGMS\n시장\n규모\nCGMS\n중장기\n매출계획\n2028년\n(단위:\n$ million)\n(단위:\n억원,\n%)\n점유율\n1%\n22,060\n3,000\n2027년\n16.5%\n18,891\n미국\n출시\nCAGR\n16,263\n2,000\n13,983\n12,017\n10,335\n8,873\n2024년\n1,200\n7,566\n유럽\n출시\n2023년\nCGM\n출시\n400\n150\n9\n2022\n2023\n2024\n2025\n2026\n2027\n2028\n2029\n2023\n2024\n2025\n2026\n2027\n2028\n출처: Analysis\nGlobal\nBlood\nGlucose\nMonitoring\nSystems\nMarket,\n2019-2030\n회사\n자체\n추정\nIsens\n9",
  "page_10": "4.\nCGM\n비디오\nIsens\n10",
  "page_11": "5.\n혈당\n측정기\n타입\n(CGM\nVS\nBGM)\n혈당값을\n실시간\n연속적으로\n측정하는\n기기\nal Sketch\n9:41 AM\n100%\n홍길동\n11.13\n11.14\nCE\n((p))\n무선송신기(트랜스미터)\n103\nmg/dL\n혈당측정센서\n500\n어플리케이터\n피부\n400\n(1~2mm)\n300\n4~6mm\n피하지방\nCareSens\n(약\n15\nmm)\n오후7\n센서\n구분\nCGM(연속혈당\n측정기)\nBGM(자가혈당\n측정기)\n측정\n방식\n센서를\n피부\n아래\n피하지방에\n위치시켜\n연속해서\n혈당값\n측정\n손가락\n끝에서\n피를\n내어\n혈당값\n측정\n사용\n대상\n1형\n당뇨\n환자(Type\n1),\n중증\n2형\n당뇨환자(Type\n2)\n모든\n당뇨\n환자군\n측정\n부위\n팔뚝\n손가락\n측정\n샘플\n세포간액(혈액이\n아님)\n모세혈\n센서\n교체주기\n센서\n장착\n후,\n15일\n1회\n사용\n장점\n혈당\n추이\n분석\n용이,\n저/고혈당\n알림기능,\n채혈\n통증\n없음,\n쉬운\n데이터\n공유\n높은\n정확도\n및\n낮은\n가격\n단점\n높은\n가격,\n피부\n트러블,\nBGM대비\n낮은\n정확도\n빈번한\n측정,\n채혈\n통증,\n저혈당\n쇼크\nIsens\n11",
  "page_12": "6. CareSens\nAir\n정확도와\n스펙\n정확도:\nMARD\n9.82\n%\nMARD\n값이\n낮을수록\n기준\n장치와\n높은\n일치도를\n나타냅니다.\n9.82%\nMARD\n대상:\n성인\n만\n19세\n이상\n*임상시험\n프로토콜을\n준수한\n피험자(순응\n집단)\n기준\n(PPS:\nper-protocol\nset)\n혈당\n수준별\n정확도\n제품\n사양\n구분(혈당\n수준,\nmg/dL)\nMAD(mg/dL)\nor\nMARD(%)\n센서\n유효\n기간\n개봉\n전:\n제조일로부터\n12개월\n개봉\n후:\n센서\n장착\n후\n15일\n<54\n12.25\nmg/dL\n센서\n안정화\n2시간\n54~69\n13.17\nmg/dL\n측정\n범위\n40~500\nmg/dL\n70~180\n9.96\n%\n데이터\n전송\n간격\n5분에\n1회\n181~250\n8.43\n%\n메모리\n혈당\n데이터\n12시간\nV\n>\n250\n10.15\n%\n보청\n첸서\n안정화\n직후\n보정\n2번\n초기\n2번은\n12시간\n주기\n*월당값\n69\nmg/dL은\nMAD\n(mg/dL)로,\n그\n이후부터\n24시간\n주기\n혈당값\n2\n70\nmg/dL은\nMARD\n(%)로\n표시됩니다.\n사용\n환경\n온도:\n10~42\n°C\n습도:\n10~95\nRH%\n방수\n등급\nIP48\nConfidence\nEvery\nMoment·\ni sens\n12",
  "page_13": "7. CGM\n사업\n현황\n2023년\n9월\nCareSens\nAir\n한국\n시장\n런칭\n후,\n유럽\n및\n글로벌\n시장\n확대\n진입\n중\nSG\n.\n주요 진행 경과\n12:10\nCareSerrs\n5 May\n4 May\n3 May\n·\n23. 9월:\n국내\n출시\n(1p)\n103\n·\n24. 2월:\n카카오헬스케어\n'파스타'\n연동\n·\n24. 2월:\n유럽\nCE\nMDR\n허가\n·\n24.3-4월:\n유럽\n주요\n국가\n계약\n·\n24. 5월:\n국내\n한독\nPL,\n헝가리\n출시\nCareSens\nAli\n12PM\nIOAM\n국내 사업\n현황\n.\n·\n일간\n활성\n사용자\n수:\n2,300명\n-2분기\n기준\n·\n누적\n활성\n사용자\n수:\n10,000명\n이상\n·\n국내\n누적\n10만\n대\n판매\n돌파\n-\n7월\n기준\nIsens\n13",
  "page_14": "8. CGM\n국내외\n영업\n&\n마케팅\n계획\nCGM\n시장의\n유연한\n대응을\n위해\nCareSens\n및\nPL\n브랜드로\n다양한\n판매\n채널을\n통한\nCGM\n제품\n공급\n9\n103\n1\nCareSens TM\nAir\n2\nPL 브랜드\nPRIVATE\nLABEL\n·\n기\n협력\n대리점\n·\n글로벌\n의료기기\n제조사/제약사\n·\n디지털헬스\n서비스\n업체\nkakaohealthcare\n·\n인슐린\n공급\n디바이스\n제조사\n·\n병원\n및\n약국\n체인\n·\n글로벌\n의료기기\n유통\n업체\n·\n온라인\n몰(자사몰,\n오픈마켓)\n·\n디지털\n헬스\n제품\n및\n서비스\n업체\n·\n기업\n및\n건강\n보험사\nIsens\n14",
  "page_15": "9. CGM\n국내외\n영업\n&\n마케팅\n계획\n한국에서의\nCGM\n사업\n경험을\n기반으로\n글로벌\n사업\n확대\n추진\n24년\n:\n14개국\n출시\n*\n3분기\n출시\n확정:\n독일,\n영국,\n네덜란드,\n칠레\n25년\n:\n20개국\n이상\n출시\n케어센스\n에어\n2\n미국\n27년\n유럽\n&\nCIS\n헝가리,\n독일,\n네덜란드,\n영국,\n24년\n8개국\n케어센스\n에어\n핀란드,\n이탈리아,\n에스토니아,\n폴란드\n25년\n크로아티아,\n스페인,\n체코,\n러시아\n4개국\n중남미\n24년\n칠레,\n멕시코\n2개국\n아프리카\n&\n중동\n아시아\n&\n오세아니아\n알제리,\n모로코,\n이집트\n25년\n5개국\n이란,\n사우디아라비아\n24년\n뉴질랜드,\n호주,\n베트남,\n태국,\n말레이시아\n5개국\n25년\n인도, 인도네시아,\n일본\n3개국\nIsens\n15",
  "page_16": "10.\nCareSens\n4월\n제품\n중\nAir\n사용자\n출시\n사용자\n이후\n보정\n보정\n약\n가능\n30만\n제품\n가능\n데이터를\n및\n제품\nNon-adjunctive\n근거로,\n알고리즘\n사용목적\n고도화\n변경\n식약처/CE\nMARD\n9.3%\n동시\n제출\n독일\n임상시험\n데이터\n국내\n임상시험\n데이터\n600\n600\n500\nE\n500\n400\n7/6/6\n400\n300\n·!\n7p/6w\n300\n200\n·!!\ncaresens\n200\n100\ncaresnes\n500\n600\n100\n300\n400\n200\n0\n100\nCobas, mg/dL\n600\n500\n300\n400\n200\n0\nYSI, mg/dL\n100\n0\nIsens\n16",
  "page_17": "11.\nCareSens\nAir\n계획\n및\n일정\n지속적인\n제품\n경쟁력\n강화\n및\n시장\n확대를\n통한\n매출\n성장\n견인\n·\n연결성\n확대\n·\n사용성\n개선\n·\n시장\n확대\n-\n리시버\n출시\n-\n사용자\n보정\n가능\n제품\n-\n전문가용\nCGM\n출시\n-\n스마트\n워치\n지원\n-\n웜업시간\n2시간\n→\n30분\n-\n2세\n이상\n사용\n가능\n-\n주요\n헬스\n플랫폼\n연동\n-\n센서\n사용\n온도\n42\n→\n45도\n·\n전문가용\nCGM\n출시\n(Blind\nmode)\n·\n리시버\n및\n스마트\n워치용\n앱\n지원\n·\n삼성\n헬스\n플랫폼\n연동\n·\n소아\n임상\n완료\n·\n소아\n임상시험\n시작\n·\n식약처\n및\nCE\n허가\n변경\n3Q23\n2Q24\n1Q25\n2Q26\n사용자\n보정\n가능\n2세\n이상\n국내\n출시\n시장\n및\n연결성\n확대\n기능\n도입\n사용\n가능\n2023\n2024\n2025\n2026\nIsens\n17",
  "page_18": "12.\nCareSens\nAir\n2\n계획\n차세대\n(CareSens\nAir\n2)\n제품은\n미국\n시장\n진출을\n위해\nFDA의\niCGM\n기준을\n만족하고,\n세계\n최고\n사양\n기반\n치료\n및\n웰니스\n제품으로\n시장\n지배력\n강화\n(세계\n3위\n목표)\n·\n미국\n시장\n진출을\n위해\nFDA의\niCGM\n기준을\n만족하고,\n치료\n및\n웰니스\n제품으로의\n확장성\n제공\n*\niCGM\n:\n미국\nFDA에서\n정의한\n정확도와\n연결성을\n보장하는\n연속혈당측정기\n기준\n·\n정확도:\niCGM\n규격(특히,\n저혈당\n정확도)\n만족\n1\n상품성\n·\n센서\n크기:\n기존\n대비\n70%\n감소\nCareSens\nAir2\n·\n사용기간\n확장:\n15일\n→\n18일\nGoGien\n차별성\n2\n·\nWarm-up\n시간\n단축:\n2시간\n→\n20분\n·\n환경을\n고려한\n친환경\n소재\n사용\n[케어센서\n에어2\n제품\n사진]\n.\n연동\n기기(인슐린\n펌프/패치\n등)\n확대\n3\n확장성\n·\n웰니스용\n및\n2형\n당뇨병\n전용\n제품\n출시\n·\nCGM/BGM\n통합\n서비스\n앱으로\n연속적인\n혈당관리\n경험\n제공\nisens\n18",
  "page_19": "13.\nCareSens\nAir\n2\n일정\n차세대\n(CareSens\nAir\n2)\n제품은\n올\n하반기\n국내\n임상시험을\n시작으로\n2026년\n부터\n국내\n및\n해외\n시장\n출시\n예정\n.\n추진\n단계\n:\n제품기획→연구/개발→임상연구→허가\n(국내,\nCE)→국내\n출시→\n유럽,\n미국\n및\n글로벌\n출시\n임상시험(성인\n및\n소아청소년)\n및\n글로벌\n출시\n간격\n최소화를\n위한\n국내\n및\nCE\n허가\n병렬\n진행\nFDA\n허가\n완료\n(FDA)\nCareSens\nAir\n2\n허가\n임상\n개시\n허가\n임상\n완료\n제품\n기획/연구/개발\n(성인)\n(성인)\n국내\n시장 출시\n미국\n시장\n(허가 완료\n후+1M)\n출시\n임상\n계획\n제출\n허가\n임상\n개시\n생산라인\n구축\n허가\n제출\n제품\n양산\n(성인, 소아/청소년)\n(소아/청소년)\n제품\n시생산\n(MFDS)\n허가\n임상\n완료\n(소아/청소년)\n'26.3Q\n'27\n4Q\n'25.10\n'24.4\n'24.11\n'25.1Q\n'25.9\n'25.4Q\n'23.12\n'24.11\n25.8\n26\n1Q\n허가\n완료\n(CE)\n허가\n제출\n허가완료\n유럽\n시장\n출시\n(CE)\n(MFDS)\n2023\n2024\n2025\n2026\n실제\n제품\n출시는\n인허가에\n소요되는\n시간에\n따라\n일정\n변경\nI sens\n19",
  "page_20": "14.\nCGM\n제품\n기반\n사업 확대\n(1)\nAgaMatrix,\nInc.\n인수\nM&A를\n통한\n글로벌\nCGM\n유통\n채널\n확대\n1\nBGM\n자회사\n·\nAgaMatrix,\n인수\nAgaMatrix\nHoldings의\nInc.\n[AgaMatrix\n지배구조]\nAgaMatrix\nHoldings,\nLLC\nBGM\n마국,\n유럽\n대형\nRetail\nChannel\n확보\n100%\n100%\nAgaMatrix,\nInc.\nWaveForm\nCGM\n해외\n시장\n진출을\n위한\nTechnologies,\nInc.\n글로벌\n영업\n네트워크\n확보\n「BGM\n사업]\n[CGM\n사업]\n지분\n100%,\n차입금\nZero\n조건\n인수($27M)\nAgaMatrix\nInc.의\n주요\n글로벌\n유통망\n·\nCVS\nPharmacy\n:\n미국\n최대\n의약품\n유통사\n글로벌\n혈당측정기\n기업의\nBGM\n자회사\n·\nSanofi:\n글로벌\n빅파마\n·\n'22년\n매출액\n약\n600억\n원,\n영업이익\n50억\n원\n·\nAlliance\nHealthcare\n:\n영국\n및\n유럽\n전역\n의약품\n유통사\n·\n선진국\n시장\n중심으로\nBGM\n시장\n점유\ni sens\n20",
  "page_21": "15.\nCGM\n제품\n기반\n사업\n확대\n(2)\n인공췌장시스템\nCGM\n기술\n및\n지분투자를\n통한\n인공췌장시스템\n시장\n진출\n2\n인슐린\n패치펌프\n회사\n'CareMedi'\n지분투자\n및\n인공췌장시스템\n파트너쉽\n구축\n인공췌장시스템\n(APS:\nArtificial\nPancreas\nSystem)\nCareMedi\n케어메디\n대표님\n32%\n케어메디\n지분\n구성\n아이센스\n20%\n췌장의\n인슐린\n분비를\n대신해\n인슐린\n펌프\n기업\n기타\n기관주주\n42%\n인공적으로\n인슐린을\n체내에\n공급하는\n시스템\n인공췌장시스템\n구성별\n협력\n내용\n인공췌장시스템\n구성\n글로벌\n인공췌장시스템\n시장\n전망\n연속혈당측정기+\n·\n아이센스\n연속혈당측정기\n(아이센스)\n인슐린\n펌프(패치)\n+\n소프트웨어\n(단위:\n$\nmillion)\n생산\n·\n케어메디\n인슐린\n펌프\n및\n패치\n(아이센스)\n4,501\nCAGR\n12.6%\n마케팅\n및\n판매\n인공췌장시스템\n구성\n전체에\n대해\n협력\n예정\n2,208\n출시 및\n허가\n계획\n(기존)\n인슐린\n펌프,\n동등성\n평가만\n필요한\n국가\n별도임상\n필요한\n국가\n연속혈당측정기\n별도\n장착\n2022\n2028(E)\n국내\n:\n'24년\n하반기\n출시\n예정\n유럽\n:\n'26년\nCE\n인증\n허가\n예정\n출처 :\nResearch\nAnd\nMarket\n미국\n:\n'26년\nFDA\n허가\n예정\nisens\n21",
  "page_22": "17.\n혈당스트립\n생산능력\n및\n생산실적\n대규모\nBGM\n스트립\n생산능력\n보유(연간\n25억\n개\n생산\n시설)\n+\nCGM\n센서\n생산능력\n50만\n개\n(1교대\n기준)\n혈당스트립\n생산능력\n및\n생산실적\n원주공장\n송도공장\n+\n중국공장\n.\n생산능력:\n연간\n약\n14억\n개\n스트립\n.\n생산능력:\n연간 약 8억\n개\n스트립\n.\n생산능력:\n연간\n약\n3억\n개\n스트립\n연간\n50만\n개\nCGM\n센서\n·\n2019년\n인허가\n취득\n완료.\n2020년\n상업용\n가\n원주공장\n생산능력(억\n개)\n송도공장\n생산능력(억\n개)\n동\n시작\n원주공장\n생산실적(억\n개)\n송도공장\n생산실적(억\n개)\n8.0\n8.0\n16.4\n16.6\n14.0\n14.0\n14.0\n13.4\n4.3\n4.0\n2.9\n2.7\n송도공장\n증설\n완료(22년\n2분기)\n+\n(생산능력:\n4억\n개\n->\n8억\n개)\n송도2공장\n준공\n(23년\n4분기)\n2021\n2022\n2023\n2021\n2022\n2023\n+\n(24년\nCGM\n센서\n자동화\n라인\n설치\n예정)\n*\n생산능력 산출\n빙법:\n일일\n평균생산수량\n×\n근무일수 X 가동월수 = 연간\n총\n생산능력, 상기\n생산능력은\n1교대\n기준(1일\n8시간 근무)\nisens\n22",
  "page_23": "18.\nCGM\n라인\n투자\n계획\n송도2공장에\nCGM\n자동화\n라인\n-\n설계\n디자인과\n설치\n계획\n중\nCGM\n라인\n(현재)\nsens\n·\nCGM\n초기\n물량\n송도공장\n생산\n송도공장\n·\n반\n자동\n라인\n·\n연간\nCapa:\n50만\n개\n센서\n·\n설치\n비용:\n약\n50억\n원\nCGM\n라인\n(예정)\n송도2공장\n·\nCGM\n대규모\n양산\n송도2공장\n셋업\n예정\n·\n자동\n라인\n(설계\n디자인\n&\n기기\n발주\n완료)\n·\n연간\nCapa.:\n520만\n개\n센서\n(26년\n까지)\nIsens\n23",
  "page_24": "19. CGM\n라인\n투자\n계획\n송도2공장\nCGM\n생산라인\n투자\n계획\nCGM\n관련\n송도공장\n송도2공장\n(예상)\n항목\n제품\n2023년\n2024년\n2025년\n2026년\nCareSens\nAir\n500,000\n1,000,000\n1,500,000\n2,000,000\n연간\nCapa.\n(누적\n센서\nCareSens\nAir\n2\n1,700,000\n3,200,000\n개수)\n합계\n(누적)\n500,000\n1,000,000\n3,200,000\n5,200,000\nIsens\n24",
  "page_25": "i·sens\nSensing\nAhead,\nCaring\nMore\nilli-\n1.\nCompany\nOverview\n2.\nBusiness\nOverview\n1)\n혈당\n부문\nIll-Illi.\n2)\nPOCT\n부문\n3.\nFinancial\nOverview\nAppendix",
  "page_26": "1. POCT\n개념\n및\n아이센스\n전략\n병원\n시장\n확대를\n통해\n전문가\n신뢰도\n상승\n효과\nPOCT(Point-Of-Care\nTesting)\n개념\n·\n현장진단검사:\n환자\n가까이에서\n신속하게\n시행하여\n진단\n및\n치료에\n이용할\n수\n있는\n검사\n·\n중앙진단장비에\n비해\n결과값을\n빠르게\n알\n수\n있음\nPOCT\n중앙검사실\n병원시장\n소비자\n아이센스\nPOCT\n사업\n전략\n확대\n시장\n확대\n·\n병원용\n진단제품을\n통해\n전문가가\n신뢰하는\n기업으로\n도약\n브랜드\n·\n소비자\n시장까지\n확대를\n통해\n브랜드\n인지도\n상승하는\n선순환\n효과\n인지도\n상승\n면역\n제품군\n특징\nHbA1c\n아이센스\nPOCT\nHand-Held\n측정기\n(심혈관)\n진단기\n혈액전해질\n·\n당뇨,\n당뇨합병증,\n응급\n관리용\n진단제품\n등\n병원용\n연계상품\n혈당기,\n/가스\n케톤측정기\n분석기\n·\n소모품\n필요한\n진단장비(센서,\n카트리지,\n시약\n등)\n지속적인\n매출과\n이익\n발생\n병원용\n당뇨병\n&\n신속,\n편리한\n혈액응고\n혈당기\n관리\n응급관리\n측정기\nisens\n26",
  "page_27": "2. POCT\n제품:\n혈액전해질/가스\n분석기\n중대형\n기기에서\n소형\n기기로\n시장\n수요가\n변화\n중\n혈액가스\n진단\n시장\n혈액전해질\n분석기\n혈액가스\n분석기\n글로벌\n시장\n규모:\n$1.4\nbillion\n*\n(POCT\n분야에서\n두\n번째로\n큰\n시장규모)\nSTART\nwen\n목적:\n혈액\n속의\n산소,\n이산화탄소,\npH농도\n등의\n항목에서\n불균형이\n있는지\n판단하는\n검사\nCarrhige\nCarePak\n이\n불균형은\n신장질환,\n심장질환,\n호흡장애,\n110\n15\n쇼크\n등을\n통해\n나타남\n-\n사용처:\n중환자실,\n응급실,\n수술실\n등\n병의원\n·\n2009년\n2월\n출시\n·\n2020년\n업그레이드\n제품\n출시\n·\n설치\n대수\n기준\n국내\n판매량\n1위\n·\n혈액가스\n측정\n항목:\n혈액전해질\n진단\n시장\npH,\npCO2,\np02,\nHct.\nNa,\nK.\nCl.\niCa.\n·\n전해질\n진단\n항목:\nGlucose,\nLactate\nHct,\nNa,\nK,\nCI:\n기존\n제품\n+\n목적:\n몸의\n수분\n상태,\n근육&신경\n관련\n작용,\n산소\nCa,\nMg\n추가:\n신제품\n개발\n중\n공급\n등에\n작용하는\n항목을\n검사\n사용처:\n일반\n내과,\n클리닉\n등\n병의원\n*\n출처:\nTriMark\nPublications\nPoint\nof\nCare\nDiagnostic\nTesting\nWorld\nMarkets(2013)\nIsens\n27",
  "page_28": "3. POCT\n제품:\n고부가가치\n전문가용\n진단\n제품\nPOCT\n제품\n라인업\n다양화,\n병원용\n혈당\n측정기의\n고성장\n기대\n병원용\n당뇨관리용\nPOCT제품\n혈액응고\n진단제품\n당화혈색소(HbA1c)\n분석기\n병원용\n혈당\n측정기\nPT/INR\n혈액응고\n측정기\n+\nACR(당뇨합병증)\n카트리지\n1.8\ng-Sense\nCong-Sense\n·\n적혈구\n내에\n당이\n붙은\n형태로\n당화혈색소\n측정\n·\n병원용\n혈당\n&\n케톤\n측정기기\n·\n미국\n자회사\nCoaguSense의\n제품\n측정으로\n3개월간\n혈당값\n도출\nWiFi,\nUSB\n등을\n통해\n데이터\n실시간\n전송,\n·\nProthrombin\nTime\ntests\n(PT\ntests):\n혈우병,\n혈소판\n1회\n과거\n·\n·\n자동\n소프트웨어\n업데이트\n등\n장점으로\n증가/무력증\n등\n출혈질환에\n대한\n검사,\n주로\n와파린\n복\n·\nACR:\n알부민과\n크레아티닌\n수치의\n비율로서\n병원\n내\n데이터\n관리\n용이\n용\n환자가\n사용\n신장\n기능을\n보다\n정확히\n진단\n·\n글로벌\n시장\n규모:\n$1B\n2)\n·\nAll-in-one\n카트리지,\n빠르고\n정확한\n결과값\nHELDEC\n·\n글로벌\n시장규모:\n$474M\n1)\n日\n·\nCoaguSense\n기대사항\nbased\nCareSens\nData\nManager\nPT\nversion\n2\n제품\nFDA\n허가\n('19년\n1분기)후\n매출확대\n1) 출처:\nGlobal\nPOC\nGlycated\nHemoglobin\nAnalyzer\nMarket\nResearch\nReport(2018)\n2) 출처:\nTriMark\nPublications\nPoint\nof\nCare\nDiagnostic\nTesting\nWorld\nMarkets(2013)\nIsens\n28",
  "page_29": "4.\nPOCT\n제품:\n면역\n측정기\n제품\n소개\n·\n심혈관\n질환\n주요\n바이오\n마커를\n측정하여\n진단하는\n분석기\n추가\n추가하여\ni sens\n·\n향후\n바이오\n마커를\n확장이\n가능한\n플랫폼\nTEST HOME\n10:05 AM\nLANE1\nLANE2\nLANE3\nLANE4\nReady\nReady\nReady\nSample Parlent\nSample Patient\nSample: Patient\nC\nPlacna\nSID\nSample 1\n제품\n특장점\nIvisenIA-1400\n·\n내부에서\n원심분리\n방식으로\nHematocrit\nBias가\n없어\n타사장비\n대비\n전혈\n정확도가\n우수함\n·\n독립적인\n4\nChannel\n구동으로\n대기\n없이\n4개\n샘플\n동시\n측정\n(응급\n환경에\n적합)\n·\n신속한\n결과값\n도출/\n완전\n자동화/\nCompact\n사이즈\ni sens\n29",
  "page_30": "i·sens\nSensing\nAhead,\nCaring\nMore\nilli-\n1.\nCompany\nOverview\n2.\nBusiness\nOverview\n1)\n혈당\n부문\n2)\nPOCT\n부문\n3.\nFinancial\nOverview\nAppendix",
  "page_31": "1.\n연간\n실적\n2023년\n연간실적\n(단위:\n억원,\n%)\nFY\n2023\nFinancial\nHighlights\nFY\n2023\nFY\n2022\nYoY\n-\n매출\n매출\n2,651\n2,648\n+0.1%\n·\n혈당부문\n매출\n+3%\nyoy,\nPOCT부문\n+13%\nyoy\n·\n지역\n별로\n아프리카\n및\n중동\n&\n남미가\n높은\n성장률을\n보였음\n영업이익\n109\n199\n-43%\nOPM(%)\n4.1%\n7.5%\n-\n영업이익\n순이익\n34\n159\n-79%\n·\nOP:\n송도2공장\n준공\n고정비\n증가,\nAgaMatrix\n인수비용\n및\n재고자산에\n미실현손익\n발생,\nCGM\n연구개발비\n및\n임상비용\n으로\n경상개발비\n증가\n등\n으로\n전년대비\n영업이익은\n감소\nFY\n2024\nFinancial\nHighlights\n2024년\n실적\n가이던스\n(단위:\n억원,\n%)\n-\n매출\nFY\n2024(E)\nFY\n2023\nYoY\n·\n혈당부문\n+7%\nyoy,\nPOCT\n+34%\nyoy\n매출\n3,100\n2,651\n+17%\n-\n영업이익\n영업이익\n160\n109\n+47%\n·\nCGM\n임상비용\n증가,\nBGM\n미터\n원가\n증가,\n송도2공장\n감가\nOPM\n5.2%\n4.1%\n상각,\nCoaguSense\nR&D\n비용,\nAgaMatrix\nSales\n&\nMarketing\n비용\n증가로\n이익률은\n다소\n보수적으로\n제시함.\nisens\n31",
  "page_32": "2.\n지역별\n매출\n현황\n(2024년\n2분기)\nYoY\n6%\nYoY\n20%\nYoY\n1%\n아시아\n123\n130\n유럽\n18%\n10%\n71\n72\n2Q23\n2Q24\n북미\n217\n261\n38%\nYoY\n20%\n2Q23\n2Q24\n2Q23\n2Q24\n146\n한국\n21%\n122\n2Q23\n2Q24\nYoY\n-3%\n점유율\n1위\n아프리카\n및 중동\n5%\n38\n3\n(MS\n47%)\nisens\n중남미\nYoY-17%\nTotal\nYoY\n11.9%\n4%\n2Q23\n2Q24\nYoY\n10%\n훰\n29\n오세아니아\n2Q23\n2Q24\n3%\n19\n21\n뉴질랜드\n2Q23\n2Q24\n699\n점유율\n1위\n684\n24년\n2분기\n23년\n2분기\n아이센스\n해외\n법인\n*\n24년\n2분기\n연결\n매출금액\n%\n연결\n매출\n비중\n(단위:억)\nisens\n32",
  "page_33": "3. 분기별\n실적\n현황\n분기별\n매출\n매출총이익률(%)\n분기별\n영업이익\n영업이익률(%)\n매출(억)\n영업이익(억)\n37.8%\n36.0%\n41.3%\n38.3%\n40.0%\n41.0%\n40.0%\n40.8%\n5.5%\n-1.7%\n7.4%\n6.1%\n-0.7%\n4.5%\n1.2%\n2.8%\n749\n699\n685\n684\n657\n670\n45\n625\n38\n38\n606\n30\n20\n8\n-11\n-4\n3Q22\n4Q22\n1Q23\n2Q23\n3Q23\n4Q23\n1Q24\n2Q24\n3Q22\n4Q22\n1Q23\n2Q23\n3Q23\n4Q23\n1Q24\n2Q24\n2024년\n2분기\n실적\n보고\n2024년\n2분기\n실적\n분석\n·\n24년\n2분기\n매출액은\n전년\n동기\n대비\n+12%\n증가\n·\n24년\n2분기\nAgaMatrix\n매출\n부진\n·\n24년\n2분기\n영업이익\n20억원\n기록\n·\n24년\n2분기\nCGM\n매출\n18억원\n달성\n·\n24년\n2분기\n당기순손실\n3억원\n기록\n·\nAgaMatrix\n스트립\n매출\n부진으로\n영업이익\n29억\n감소\n(AgaMatrix\n영업손실로\n29억\n당기순이익\n감소\n영향\n발생)\n(5월에\n구조조정으로\n하반기부터\n영업이익\n회복\n예상)\n*\nK-IFRS\n연결\n재무제표\n기준\nisens\n33",
  "page_34": "Appendix\n1.\n회사개요\n회사명\n아이센스\n[KOSDAQ 099190]\n아이센스\n대표이사\n차근식,남학현\n주요사업\n전기화학진단\n센서\n설립일\n2000년 05월\n판매\n법인\n종합\n법인\n주요\n관계\n및\n투자회사\n상장일\n2013년01월\n자본금\n13,759\n백만원\ni-SENS\nAgaMatrix,\n-\n프리시젼바이오(28%)\n임직원수\nInc.\n893 명\nUSA\n-\n케어메디(19%)\n주소\n서울시\n서초구\n반포대로\n28길\n43\n아이센스\n빌딩\ni-SENS\nMexico\nCoaguSense\n홈페이지\nwww.i-sens.com\ni-SENS\ni-SENS\nChile\nHong\nKong\nArkray\n공동창업자\n(전략적\ni-SENS\n차근식(CEO)\n제휴)\nIndia\ni-SENS\n남학현(CEO)\nJiangsu(China)\ni-SENS\n*26%\n10%\nGermany\ni-SENS\nIsens\nMalaysia\n상장\n주식수\n22%\n외국인\ni-SENS\n27,637,273\nBiz\n42%\n국내기관\n개인\n등\n(2024년\n6월\n30일\n기준)\n*특수관계인\n포함\n지분율\nI sens\n34",
  "page_35": "Appendix\n2.\n주요\n임원진\n및\nR&D\n투자\n추이\n국내\n바이오센서\n업계\n최고의\n연구진\n및\n지속적인\nR&D투자\n경영진\n주요\n약력\n차근식(회장,\nCEO)\n남학현(대표이사,\nCEO)\n.\n고려대학교\n화학과\n학사,\n석사\n·\n서울대학교\n화학과\n학사\n·\nMichigan\nState\nUniversity\n이학박사\n·\nUniversity\nof\nMichigan\n화학과\n박사\n·\n'92~'15\n광운대학교\n화학과\n교수\n.\n'91~'15\n광운대학교\n화학과\n교수\n.\n현재\n광운대학교\n명예교수\n.\n현재\n광운대학교\n명예교수\n(주)아이센스\n사장,\n대표이사\n·\n'00~현재\n.\n'00~현재\n아이센스\n대표이사(CEO)\n'08\n보건의료과학기술\n연구개발\n우수연구자\n표창\n·\n'11\n대한민국\n벤처창업대전\n표창(지식경제부\n장관)\n(보건복지부\n장관)\n·\n'14\n의료기기산업\n유공자\n표창(보건복지부\n장관)\n·\n'11\n산학연협력\n유공자\n표창(교육과학기술부\n장관)\n'16\n전자IT의\n날\n유공자\n표창(산업통상자원부\n대통령)\n·\n'11\n산업기술진흥유공자\n표창(국무총리)\n·\n·\n'19\n제115회\n한국을\n빛낸\n이달의\n무역인\n상(한국무역\n협회)\n·\n'19\n2019년\n과학/정보통신의\n날\n표창(국무총리)\n연구개발\n비용\n인력\n구성\n15.8%\n(단위:명,\n2024년\n6월\n30일\n기준)\n10.7%\n10.5%\n11.3%\n10.9%\n893\n명\n184\n203\n250\n229\n임원\n사무직\n영업직\n연구직\n생산직\n156\n11\n144\n\"\n153\n516\n학사\n외\n석사\n박사\n2020\n2021\n2022\n2023\n2Q24\n773\n100\n20\n매출액\n대비\n연구개발\n비용(%)\n연구개발\n비용누적(억원)\n*별도기준\nisens\n35",
  "page_36": "Appendix\n3.\n연결\n재무제표\n재무상태표\n(단위:\n백만\n원)\n손익계산서\n(단위:\n백만\n원)\n구분\n2020\n2021\n2022\n2023\n2Q24\n구분\n2020\n2021\n2022\n2023\n2Q24\n유동자산\n159,943\n207,654\n217,187\n207,526\n256,785\n매출액\n203,708\n232,935\n264,837\n265,120\n69,900\n비유동자산\n147,087\n221,526\n232,383\n281,045\n288,211\n매출원가\n107,920\n130,870\n159,351\n159,061\n41,378\n자산총계\n307,030\n429,180\n449,570\n498,816\n555,241\n매출총이익\n95,787\n102,064\n105,486\n106,059\n28,522\n유동부채\n31,626\n38,391\n74,563\n139,305\n140,333\n비유동부채\n52,278\n106,048\n70,251\n56,016\n99,332\n판매비와관리비\n65,331\n67,238\n85,679\n95,130\n26,551\n부채총계\n83,904\n144,439\n144,814\n195,321\n239,665\n영업이익\n30,456\n34,827\n19,807\n10,929\n1,970\n자본금\n6,869\n6,869\n6,877\n13,759\n13,819\n영업외손익\n6,669\n(2,653)\n1,696\n(2,819)\n(1,472)\n자본잉여금\n46,063\n46,205\n47,013\n41,697\n43,468\n기타자본항목\n(6,551)\n(6,569)\n(4,653)\n(5,092)\n2,587\n지분법손익\n(2,180)\n(1,433)\n(2,350)\n(1,978)\n(684)\n기타포괄손익\n(3,715)\n23,303\n22,631\n21,861\n26,881\n법인세비용\n34,945\n30,741\n19,153\n6,133\n(185)\n차감전순이익\n이익잉여금\n176,827\n198,525\n213,942\n211,577\n208,535\n법인세비용\n7,650\n5,590\n3,246\n2,728\n214\n비지배지분\n3,634\n16,408\n18,946\n19,145\n19,737\n자본총계\n223,126\n284,740\n304,756\n303,495\n315,576\n당기순이익\n27,296\n25,151\n15,908\n3,404\n29\nK-IFRS\n연결\n재무제표\n기준\ni sens\n36"
}